2025年9月5日，宁波天益医疗器械股份有限公司（证券代码：301097）正式宣布，其新加坡全资子公司Primacron Global PTE. LTD.（潜莱马克隆国际有限公司）已完成对意大利企业Bellco S. R. L.旗下CRRT-滤器业务资产的收购。标志着天益医疗在全球重症肾脏病治疗领域迈出关键 ...

【宝莱特：正在紧密进行CRRT机型的自主研发】财联社6月19日电，宝莱特(300246.SZ)在机构调研中表示，在肾病医疗板块，公司将持续研发血液透析差异化耗材，积极探索腹膜透析、CRRT等更多肾科医疗相关领域产品技术，推进G系列高端监护仪、AED、除颤监护仪等有 ...

A new study suggests that use of unadjusted dosages of β-lactam antibiotics could reduce the risk of inadequate serum concentrations during continuous renal replacement therapy. However, risk of ...

Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week The FDA agreed to two additional protocol changes ...